DDInter1397 DDInter471
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa). It is chemically distinct from heparin by containing different protein binding properties, thus has lower cross-reactivity in heparin-intolerant patients. Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and prevention of post-operative deep venous thrombosis (DVT). While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer. The use of Orgaran™ was discontinued in the United States however it is available in several other countries including European countries and Japan. Danaparoid sodium is the common salt form in therapeutic preparations and is typically administered subcutaneously.
Paroxetine {u} (Compound) upregulates {v} (Gene) SCNN1A
SCNN1A {u} (Gene) is bound by {v} (Compound) Amiloride
Amiloride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Danaparoid
Paroxetine {u} (Compound) causes {v} (Side Effect) Angina pectoris
Angina pectoris {u} (Side Effect) is caused by {v} (Compound) Amiloride
Amiloride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Danaparoid
Paroxetine {u} (Compound) causes {v} (Side Effect) Angina pectoris
Angina pectoris {u} (Side Effect) is caused by {v} (Compound) Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Danaparoid
Paroxetine {u} (Compound) causes {v} (Side Effect) Angina pectoris
Angina pectoris {u} (Side Effect) is caused by {v} (Compound) Ponatinib
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Danaparoid
Paroxetine {u} (Compound) causes {v} (Side Effect) Angina pectoris
Angina pectoris {u} (Side Effect) is caused by {v} (Compound) Anagrelide
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Danaparoid
Paroxetine {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Triamterene
Triamterene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Danaparoid
Paroxetine {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Danaparoid
Paroxetine {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Anagrelide
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Danaparoid
Paroxetine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Danaparoid
Paroxetine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Venlafaxine
Venlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Danaparoid
Paroxetine (Compound) upregulates SCNN1A (Gene) and SCNN1A (Gene) is bound by Amiloride (Compound) and Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Paroxetine (Compound) causes Angina pectoris (Side Effect) and Angina pectoris (Side Effect) is caused by Amiloride (Compound) and Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Paroxetine (Compound) causes Angina pectoris (Side Effect) and Angina pectoris (Side Effect) is caused by Levomilnacipran (Compound) and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Paroxetine (Compound) causes Angina pectoris (Side Effect) and Angina pectoris (Side Effect) is caused by Ponatinib (Compound) and Ponatinib may lead to a major life threatening interaction when taken with Danaparoid
Paroxetine (Compound) causes Angina pectoris (Side Effect) and Angina pectoris (Side Effect) is caused by Anagrelide (Compound) and Anagrelide may lead to a major life threatening interaction when taken with Danaparoid
Paroxetine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Triamterene (Compound) and Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Paroxetine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may lead to a major life threatening interaction when taken with Danaparoid
Paroxetine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Anagrelide (Compound) and Anagrelide may lead to a major life threatening interaction when taken with Danaparoid
Paroxetine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Levomilnacipran (Compound) and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Paroxetine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Venlafaxine (Compound) and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid